Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Researchers are studying how well serum tumor marker directed disease monitoring works compared to the usual monitoring approach for patients with hormone receptor positive, HER2 negative metastatic breast cancer. This trial aims to see if monitoring patients with specific blood markers to decide when to perform scans leads to similar overall survival as the standard care. The study also explores healthcare costs and patient-reported anxiety and quality of life between these monitoring methods. Participants are randomly assigned to one of two groups. One group receives usual care with imaging at least every 12 weeks and tumor marker tests as decided by their doctor. The other group undergoes regular serum tumor marker tests every 4 to 8 weeks, and imaging is only done if these markers rise. Both groups continue their assigned monitoring until disease progression or up to 312 weeks. During the study, participants complete questionnaires about anxiety and quality of life. Researchers collect data on overall survival, healthcare costs, and patient experiences over various timeframes, including up to 312 weeks for survival and 102 weeks for patient-reported outcomes. Monitoring is consistent at facilities accessible to the study team, and participants are followed closely while on their assigned monitoring approach throughout the study period.